Intracranial B7-H3 CAR-T Shows Early Promise in Recurrent Glioblastoma
A first-in-human phase 1 trial of locoregional TX103 CAR-T establishes tolerability and a recommended dose for recurrent glioblastoma, though efficacy signals remain preliminary and relevant chiefly to neuro-oncology pharmacy practice within clinical trial settings.
📅 Journal publication: Sep 2026(online Aug 6, 2026)·Last updated: Aug 12, 2026
CAR-T cell therapy offers new hope for recurrent glioblastoma.
Recurrent glioblastoma has limited treatments, and this trial explores a novel option with CAR-T cells targeting B7-H3. TX103 was well tolerated without dose-limiting toxicities; 12-month survival rate was 66.7% with a median overall survival of 19.1 months. This study indicates potential for TX103 to be a viable therapy for recurrent glioblastoma, though larger trials are necessary to confirm efficacy. Intracranial delivery of B7-H3-targeting CAR-T cells shows promise in recurrent glioblastoma therapy.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Zhang Y, Chi X, Feng R, Xian N, Huang N, Sun S, Zhao X, Zhang P, Liu K, Ma Y, Zhang Y, Zhang K, Wang S, Chen X, Zhang J, Huang W, Huang B, Su TT, Yeung J, He J, Chen L, Ji N, Huang G
Citation:Zhang Y, Chi X, Feng R, et al. Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial. Nature medicine. 2026;32(9):3268-3275. doi:10.1038/s41591-026-04557-6